BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, discovering a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.

Biotechnology

BenevolentAI

BenevolentAI's headquarters in United Kingdom

This department focuses on analyzing and interpreting biological data through computational methods and tools.

Bioinformatics Sciences

This department is focused on conducting advanced research and development in pharmacology to support drug discovery and development initiatives.

Pharmacology Research

This department consists of high-level executives who provide strategic direction and governance for the organization.

Leadership Council

This department focuses on designing, building, and maintaining software solutions.

Software Development

This department focuses on creating and nurturing relationships to drive growth and enhance client satisfaction.

Business Development

This department manages financial planning, analysis, and reporting to guide strategic decision-making.

People (3)

Jobs (0)

Other teams

Pharmacology Research

Leadership Council

Software Development

Business Development

Finance Department